NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

First, Neuro-Oncology editorial article ARE peer-reviewed. From the Neuro-Oncology Publication Author guidelines:
"Reviews and Editorials that cover subjects of timely interest and importance to cancer researchers. (These are usually written by invitation of the Editor in Chief. Authors wishing to write a review or an editorial should send a letter to the Editor in Chief outlining the proposed article. All reviews that the editors consider suitable, whether invited or not, will be subjected to full peer review.)"
Second all of the NWBO authors are paid by NWBO directly or indirectly. In fact the corresponding author is Dr. Bosch, AN NWBO EMPLOYEE. As stated in the article:
Corresponding Author: Marnix L. Bosch, PhD, Northwest Biotherapeutics, Inc, 4800 Montgomery Ln, Bethesda, MD 20814 ([e-mail]).
"Author Contributions: Dr Bosch had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis." Dr. Bosch directed the outside statistical company that produced the dubious external comparator data, the provided the statistical manipulation of the nOS endpoint to compensate for the confounding of through the multiple dosing of the treatment arm. Something that was not done in the external comparators. It was buried on the SAP, along with the missing details on the external comparator selection criteria.